The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.

The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib. ##STR00001##

Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.

Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.